Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 163 entries
Sorted by: Best Match Show Resources per page
Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS).

The Journal of allergy and clinical immunology

, Ma C, Schoepfer AM, Dellon ES, Bredenoord AJ, Chehade M, Collins MH, Feagan BG, Furuta GT, Gupta SK, Hirano I, Jairath V, Katzka DA, Pai RK, Rothenberg ME, Straumann A, Aceves SS, Alexander JA, Arva NC, Atkins D, Biedermann L, Blanchard C, Cianferoni A, Ciriza de Los Rios C, Clayton F, Davis CM, de Bortoli N, Dias JA, Falk GW, Genta RM, Ghaffari G, Gonsalves N, Greuter T, Hopp R, Hsu Blatman KS, Jensen ET, Johnston D, Kagalwalla AF, Larsson HM, Leung J, Louis H, Masterson JC, Menard-Katcher C, Menard-Katcher PA, Moawad FJ, Muir AB, Mukkada VA, Penagini R, Pesek RD, Peterson K, Putnam PE, Ravelli A, Savarino EV, Schlag C, Schreiner P, Simon D, Smyrk TC, Spergel JM, Taft TH, Terreehorst I, Vanuytsel T, Venter C, Vieira MC, Vieth M, Vlieg-Boerstra B, von Arnim U, Walker MM, Wechsler JB, Woodland P, Woosley JT, Yang GY, Zevit N, Safroneeva E.
PMID: 34242635
J Allergy Clin Immunol. 2021 Jul 06; doi: 10.1016/j.jaci.2021.07.001. Epub 2021 Jul 06.

BACKGROUND: End points used to determine treatment efficacy in eosinophilic esophagitis (EoE) have evolved over time. With multiple novel therapies in development for EoE, harmonization of outcomes measures will facilitate evidence synthesis and appraisal when comparing different treatments.OBJECTIVE: We...

Cite
, Ma C, Schoepfer AM, et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2021;doi: 10.1016/j.jaci.2021.07.001.
, Ma, C., Schoepfer, A. M., Dellon, E. S., Bredenoord, A. J., Chehade, M., Collins, M. H., Feagan, B. G., Furuta, G. T., Gupta, S. K., Hirano, I., Jairath, V., Katzka, D. A., Pai, R. K., Rothenberg, M. E., Straumann, A., Aceves, S. S., Alexander, J. A., Arva, N. C., Atkins, D., Biedermann, L., Blanchard, C., Cianferoni, A., Ciriza de Los Rios, C., Clayton, F., Davis, C. M., de Bortoli, N., Dias, J. A., Falk, G. W., Genta, R. M., Ghaffari, G., Gonsalves, N., Greuter, T., Hopp, R., Hsu Blatman, K. S., Jensen, E. T., Johnston, D., Kagalwalla, A. F., Larsson, H. M., Leung, J., Louis, H., Masterson, J. C., Menard-Katcher, C., Menard-Katcher, P. A., Moawad, F. J., Muir, A. B., Mukkada, V. A., Penagini, R., Pesek, R. D., Peterson, K., Putnam, P. E., Ravelli, A., Savarino, E. V., Schlag, C., Schreiner, P., Simon, D., Smyrk, T. C., Spergel, J. M., Taft, T. H., Terreehorst, I., Vanuytsel, T., Venter, C., Vieira, M. C., Vieth, M., Vlieg-Boerstra, B., von Arnim, U., Walker, M. M., Wechsler, J. B., Woodland, P., Woosley, J. T., Yang, G. Y., Zevit, N., & Safroneeva, E. (2021). Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). The Journal of allergy and clinical immunology, . https://doi.org/10.1016/j.jaci.2021.07.001
, et al. "Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)." The Journal of allergy and clinical immunology vol. (2021). doi: https://doi.org/10.1016/j.jaci.2021.07.001
, Ma C, Schoepfer AM, Dellon ES, Bredenoord AJ, Chehade M, Collins MH, Feagan BG, Furuta GT, Gupta SK, Hirano I, Jairath V, Katzka DA, Pai RK, Rothenberg ME, Straumann A, Aceves SS, Alexander JA, Arva NC, Atkins D, Biedermann L, Blanchard C, Cianferoni A, Ciriza de Los Rios C, Clayton F, Davis CM, de Bortoli N, Dias JA, Falk GW, Genta RM, Ghaffari G, Gonsalves N, Greuter T, Hopp R, Hsu Blatman KS, Jensen ET, Johnston D, Kagalwalla AF, Larsson HM, Leung J, Louis H, Masterson JC, Menard-Katcher C, Menard-Katcher PA, Moawad FJ, Muir AB, Mukkada VA, Penagini R, Pesek RD, Peterson K, Putnam PE, Ravelli A, Savarino EV, Schlag C, Schreiner P, Simon D, Smyrk TC, Spergel JM, Taft TH, Terreehorst I, Vanuytsel T, Venter C, Vieira MC, Vieth M, Vlieg-Boerstra B, von Arnim U, Walker MM, Wechsler JB, Woodland P, Woosley JT, Yang GY, Zevit N, Safroneeva E. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2021 Jul 06; doi: 10.1016/j.jaci.2021.07.001. Epub 2021 Jul 06. PMID: 34242635.
Copy Download .nbib Format: NLM
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.

The Lancet. Respiratory medicine

Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M.
PMID: 34597534
Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28.

BACKGROUND: Clinical trials have shown treatment benefits of dupilumab in patients with uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma, as data for...

Cite
Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2021;10(1):11-25doi: 10.1016/S2213-2600(21)00322-2.
Wechsler, M. E., Ford, L. B., Maspero, J. F., Pavord, I. D., Papi, A., Bourdin, A., Watz, H., Castro, M., Nenasheva, N. M., Tohda, Y., Langton, D., Cardona, G., Domingo, C., Park, H. S., Chapman, K. R., Mao, X., Zhang, Y., Khan, A. H., Deniz, Y., Rowe, P. J., Kapoor, U., Khokhar, F. A., Mannent, L. P., Ruddy, M., Laws, E., Amin, N., & Hardin, M. (2022). Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. The Lancet. Respiratory medicine, 10(1), 11-25. https://doi.org/10.1016/S2213-2600(21)00322-2
Wechsler, Michael E, et al. "Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study." The Lancet. Respiratory medicine vol. 10,1 (2022): 11-25. doi: https://doi.org/10.1016/S2213-2600(21)00322-2
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28. PMID: 34597534.
Copy Download .nbib Format: NLM
Impaired SARS-CoV-2 mRNA vaccine antibody response in chronic medical conditions: a real-world analysis.

Chest

Liao SY, Gerber AN, Zelarney P, Make B, Wechsler ME.
PMID: 35016912
Chest. 2022 Jan 08; doi: 10.1016/j.chest.2021.12.654. Epub 2022 Jan 08.

No abstract available.

Cite
Liao SY, Gerber AN, Zelarney P, et al. Impaired SARS-CoV-2 mRNA vaccine antibody response in chronic medical conditions: a real-world analysis. Chest. 2022;doi: 10.1016/j.chest.2021.12.654.
Liao, S. Y., Gerber, A. N., Zelarney, P., Make, B., & Wechsler, M. E. (2022). Impaired SARS-CoV-2 mRNA vaccine antibody response in chronic medical conditions: a real-world analysis. Chest, . https://doi.org/10.1016/j.chest.2021.12.654
Liao, Shu-Yi, et al. "Impaired SARS-CoV-2 mRNA vaccine antibody response in chronic medical conditions: a real-world analysis." Chest vol. (2022). doi: https://doi.org/10.1016/j.chest.2021.12.654
Liao SY, Gerber AN, Zelarney P, Make B, Wechsler ME. Impaired SARS-CoV-2 mRNA vaccine antibody response in chronic medical conditions: a real-world analysis. Chest. 2022 Jan 08; doi: 10.1016/j.chest.2021.12.654. Epub 2022 Jan 08. PMID: 35016912.
Copy Download .nbib Format: NLM
Defining the Patchy Landscape of Esophageal Eosinophilia in Children With Eosinophilic Esophagitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Wechsler JB, Bolton SM, Gray E, Kim KY, Kagalwalla AF.
PMID: 34954340
Clin Gastroenterol Hepatol. 2021 Dec 23; doi: 10.1016/j.cgh.2021.12.023. Epub 2021 Dec 23.

BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) is a patchy disease of the esophagus with significant variability in intraepithelial eosinophilia. Three biopsies each from distal and proximal esophagus are recommended for identification of active EoE. Recent work suggests 3 biopsy...

Cite
Wechsler JB, Bolton SM, Gray E, et al. Defining the Patchy Landscape of Esophageal Eosinophilia in Children With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2021;doi: 10.1016/j.cgh.2021.12.023.
Wechsler, J. B., Bolton, S. M., Gray, E., Kim, K. Y., & Kagalwalla, A. F. (2021). Defining the Patchy Landscape of Esophageal Eosinophilia in Children With Eosinophilic Esophagitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, . https://doi.org/10.1016/j.cgh.2021.12.023
Wechsler, Joshua B, et al. "Defining the Patchy Landscape of Esophageal Eosinophilia in Children With Eosinophilic Esophagitis." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. (2021). doi: https://doi.org/10.1016/j.cgh.2021.12.023
Wechsler JB, Bolton SM, Gray E, Kim KY, Kagalwalla AF. Defining the Patchy Landscape of Esophageal Eosinophilia in Children With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2021 Dec 23; doi: 10.1016/j.cgh.2021.12.023. Epub 2021 Dec 23. PMID: 34954340.
Copy Download .nbib Format: NLM
Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Sabnis HS, Shulman DS, Mizukawa B, Bouvier N, Zehir A, Fangusaro J, Fabrizio VA, Whitlow C, Winchester M, Agresta L, Turpin B, Wechsler DS, DuBois SG, Glade-Bender J, Castellino SM, Shukla N.
PMID: 34591650
J Clin Oncol. 2021 Dec 01;39(34):3822-3828. doi: 10.1200/JCO.21.01213. Epub 2021 Sep 30.

PURPOSE: The US Food and Drug Administration-expanded access program (EAP) uses a single patient use (SPU) mechanism to provide patient access to investigational agents in situations where no satisfactory or comparable therapy is available. Genomic profiling of de novo...

Cite
Sabnis HS, Shulman DS, Mizukawa B, et al. Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. J Clin Oncol. 2021;39(34):3822-3828doi: 10.1200/JCO.21.01213.
Sabnis, H. S., Shulman, D. S., Mizukawa, B., Bouvier, N., Zehir, A., Fangusaro, J., Fabrizio, V. A., Whitlow, C., Winchester, M., Agresta, L., Turpin, B., Wechsler, D. S., DuBois, S. G., Glade-Bender, J., Castellino, S. M., & Shukla, N. (2021). Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(34), 3822-3828. https://doi.org/10.1200/JCO.21.01213
Sabnis, Himalee S, et al. "Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,34 (2021): 3822-3828. doi: https://doi.org/10.1200/JCO.21.01213
Sabnis HS, Shulman DS, Mizukawa B, Bouvier N, Zehir A, Fangusaro J, Fabrizio VA, Whitlow C, Winchester M, Agresta L, Turpin B, Wechsler DS, DuBois SG, Glade-Bender J, Castellino SM, Shukla N. Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. J Clin Oncol. 2021 Dec 01;39(34):3822-3828. doi: 10.1200/JCO.21.01213. Epub 2021 Sep 30. PMID: 34591650.
Copy Download .nbib Format: NLM
Biomarkers to Predict Response to ICS and LAMA in Adolescents and Adults with Mild Persistent Asthma.

Annals of the American Thoracic Society

Krishnan JA, Lazarus SC, Blake KV, Sorkness CA, Covar R, Dyer AM, Lang JE, Lugogo NL, Mauger DT, Wechsler ME, Wenzel SE, Cardet JC, Castro M, Israel E, Phipatanakul W, King TS.
PMID: 34793687
Ann Am Thorac Soc. 2021 Nov 18; doi: 10.1513/AnnalsATS.202105-613OC. Epub 2021 Nov 18.

Rationale Whether biomarkers can be used to predict response to inhaled corticosteroids (ICS) or long-acting muscarinic antagonists (LAMA) in mild persistent asthma is unclear. Objectives In a pre-specified exploratory analysis of a randomized clinical trial of 295 participants >12...

Cite
Krishnan JA, Lazarus SC, Blake KV, et al. Biomarkers to Predict Response to ICS and LAMA in Adolescents and Adults with Mild Persistent Asthma. Ann Am Thorac Soc. 2021;doi: 10.1513/AnnalsATS.202105-613OC.
Krishnan, J. A., Lazarus, S. C., Blake, K. V., Sorkness, C. A., Covar, R., Dyer, A. M., Lang, J. E., Lugogo, N. L., Mauger, D. T., Wechsler, M. E., Wenzel, S. E., Cardet, J. C., Castro, M., Israel, E., Phipatanakul, W., King, T. S. (2021). Biomarkers to Predict Response to ICS and LAMA in Adolescents and Adults with Mild Persistent Asthma. Annals of the American Thoracic Society, . https://doi.org/10.1513/AnnalsATS.202105-613OC
Krishnan, Jerry A, et al. "Biomarkers to Predict Response to ICS and LAMA in Adolescents and Adults with Mild Persistent Asthma." Annals of the American Thoracic Society vol. (2021). doi: https://doi.org/10.1513/AnnalsATS.202105-613OC
Krishnan JA, Lazarus SC, Blake KV, Sorkness CA, Covar R, Dyer AM, Lang JE, Lugogo NL, Mauger DT, Wechsler ME, Wenzel SE, Cardet JC, Castro M, Israel E, Phipatanakul W, King TS. Biomarkers to Predict Response to ICS and LAMA in Adolescents and Adults with Mild Persistent Asthma. Ann Am Thorac Soc. 2021 Nov 18; doi: 10.1513/AnnalsATS.202105-613OC. Epub 2021 Nov 18. PMID: 34793687.
Copy Download .nbib Format: NLM
Mast cell activation is associated with post-acute COVID-19 syndrome.

Allergy

Wechsler JB, Butuci M, Wong A, Kamboj AP, Youngblood BA.
PMID: 34820848
Allergy. 2021 Nov 25; doi: 10.1111/all.15188. Epub 2021 Nov 25.

No abstract available.

Cite
Wechsler JB, Butuci M, Wong A, et al. Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy. 2021;doi: 10.1111/all.15188.
Wechsler, J. B., Butuci, M., Wong, A., Kamboj, A. P., & Youngblood, B. A. (2021). Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy, . https://doi.org/10.1111/all.15188
Wechsler, Joshua B, et al. "Mast cell activation is associated with post-acute COVID-19 syndrome." Allergy vol. (2021). doi: https://doi.org/10.1111/all.15188
Wechsler JB, Butuci M, Wong A, Kamboj AP, Youngblood BA. Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy. 2021 Nov 25; doi: 10.1111/all.15188. Epub 2021 Nov 25. PMID: 34820848.
Copy Download .nbib Format: NLM
Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion.

The journal of allergy and clinical immunology. In practice

Buhl R, Bel E, Bourdin A, Dávila I, Douglass JA, FitzGerald JM, Jackson DJ, Lugogo NL, Matucci A, Pavord ID, Wechsler ME, Kraft M.
PMID: 34763123
J Allergy Clin Immunol Pract. 2021 Nov 08; doi: 10.1016/j.jaip.2021.10.059. Epub 2021 Nov 08.

Severe asthma often remains uncontrolled despite effective treatments and evidence-based guidelines. A group of global experts in asthma and biologic medications from 9 countries considered the most relevant clinical variables to manage severe asthma in adult patients and guide...

Cite
Buhl R, Bel E, Bourdin A, et al. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. J Allergy Clin Immunol Pract. 2021;doi: 10.1016/j.jaip.2021.10.059.
Buhl, R., Bel, E., Bourdin, A., Dávila, I., Douglass, J. A., FitzGerald, J. M., Jackson, D. J., Lugogo, N. L., Matucci, A., Pavord, I. D., Wechsler, M. E., & Kraft, M. (2021). Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. The journal of allergy and clinical immunology. In practice, . https://doi.org/10.1016/j.jaip.2021.10.059
Buhl, Roland, et al. "Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion." The journal of allergy and clinical immunology. In practice vol. (2021). doi: https://doi.org/10.1016/j.jaip.2021.10.059
Buhl R, Bel E, Bourdin A, Dávila I, Douglass JA, FitzGerald JM, Jackson DJ, Lugogo NL, Matucci A, Pavord ID, Wechsler ME, Kraft M. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. J Allergy Clin Immunol Pract. 2021 Nov 08; doi: 10.1016/j.jaip.2021.10.059. Epub 2021 Nov 08. PMID: 34763123.
Copy Download .nbib Format: NLM
Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS).

The Journal of allergy and clinical immunology

, Ma C, Schoepfer AM, Dellon ES, Bredenoord AJ, Chehade M, Collins MH, Feagan BG, Furuta GT, Gupta SK, Hirano I, Jairath V, Katzka DA, Pai RK, Rothenberg ME, Straumann A, Aceves SS, Alexander JA, Arva NC, Atkins D, Biedermann L, Blanchard C, Cianferoni A, Ciriza de Los Rios C, Clayton F, Davis CM, de Bortoli N, Dias JA, Falk GW, Genta RM, Ghaffari G, Gonsalves N, Greuter T, Hopp R, Hsu Blatman KS, Jensen ET, Johnston D, Kagalwalla AF, Larsson HM, Leung J, Louis H, Masterson JC, Menard-Katcher C, Menard-Katcher PA, Moawad FJ, Muir AB, Mukkada VA, Penagini R, Pesek RD, Peterson K, Putnam PE, Ravelli A, Savarino EV, Schlag C, Schreiner P, Simon D, Smyrk TC, Spergel JM, Taft TH, Terreehorst I, Vanuytsel T, Venter C, Vieira MC, Vieth M, Vlieg-Boerstra B, von Arnim U, Walker MM, Wechsler JB, Woodland P, Woosley JT, Yang GY, Zevit N, Safroneeva E.
PMID: 34242635
J Allergy Clin Immunol. 2021 Jul 06; doi: 10.1016/j.jaci.2021.07.001. Epub 2021 Jul 06.

BACKGROUND: End points used to determine treatment efficacy in eosinophilic esophagitis (EoE) have evolved over time. With multiple novel therapies in development for EoE, harmonization of outcomes measures will facilitate evidence synthesis and appraisal when comparing different treatments.OBJECTIVE: We...

Cite
, Ma C, Schoepfer AM, et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2021;doi: 10.1016/j.jaci.2021.07.001.
, Ma, C., Schoepfer, A. M., Dellon, E. S., Bredenoord, A. J., Chehade, M., Collins, M. H., Feagan, B. G., Furuta, G. T., Gupta, S. K., Hirano, I., Jairath, V., Katzka, D. A., Pai, R. K., Rothenberg, M. E., Straumann, A., Aceves, S. S., Alexander, J. A., Arva, N. C., Atkins, D., Biedermann, L., Blanchard, C., Cianferoni, A., Ciriza de Los Rios, C., Clayton, F., Davis, C. M., de Bortoli, N., Dias, J. A., Falk, G. W., Genta, R. M., Ghaffari, G., Gonsalves, N., Greuter, T., Hopp, R., Hsu Blatman, K. S., Jensen, E. T., Johnston, D., Kagalwalla, A. F., Larsson, H. M., Leung, J., Louis, H., Masterson, J. C., Menard-Katcher, C., Menard-Katcher, P. A., Moawad, F. J., Muir, A. B., Mukkada, V. A., Penagini, R., Pesek, R. D., Peterson, K., Putnam, P. E., Ravelli, A., Savarino, E. V., Schlag, C., Schreiner, P., Simon, D., Smyrk, T. C., Spergel, J. M., Taft, T. H., Terreehorst, I., Vanuytsel, T., Venter, C., Vieira, M. C., Vieth, M., Vlieg-Boerstra, B., von Arnim, U., Walker, M. M., Wechsler, J. B., Woodland, P., Woosley, J. T., Yang, G. Y., Zevit, N., & Safroneeva, E. (2021). Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). The Journal of allergy and clinical immunology, . https://doi.org/10.1016/j.jaci.2021.07.001
, et al. "Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)." The Journal of allergy and clinical immunology vol. (2021). doi: https://doi.org/10.1016/j.jaci.2021.07.001
, Ma C, Schoepfer AM, Dellon ES, Bredenoord AJ, Chehade M, Collins MH, Feagan BG, Furuta GT, Gupta SK, Hirano I, Jairath V, Katzka DA, Pai RK, Rothenberg ME, Straumann A, Aceves SS, Alexander JA, Arva NC, Atkins D, Biedermann L, Blanchard C, Cianferoni A, Ciriza de Los Rios C, Clayton F, Davis CM, de Bortoli N, Dias JA, Falk GW, Genta RM, Ghaffari G, Gonsalves N, Greuter T, Hopp R, Hsu Blatman KS, Jensen ET, Johnston D, Kagalwalla AF, Larsson HM, Leung J, Louis H, Masterson JC, Menard-Katcher C, Menard-Katcher PA, Moawad FJ, Muir AB, Mukkada VA, Penagini R, Pesek RD, Peterson K, Putnam PE, Ravelli A, Savarino EV, Schlag C, Schreiner P, Simon D, Smyrk TC, Spergel JM, Taft TH, Terreehorst I, Vanuytsel T, Venter C, Vieira MC, Vieth M, Vlieg-Boerstra B, von Arnim U, Walker MM, Wechsler JB, Woodland P, Woosley JT, Yang GY, Zevit N, Safroneeva E. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2021 Jul 06; doi: 10.1016/j.jaci.2021.07.001. Epub 2021 Jul 06. PMID: 34242635; PMCID: PMC8733049.
Copy Download .nbib Format: NLM
Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.

The journal of allergy and clinical immunology. In practice

Porsbjerg CM, Menzies-Gow AN, Tran TN, Murray RB, Unni B, Audrey Ang SL, Alacqua M, Al-Ahmad M, Al-Lehebi R, Altraja A, Belevskiy AS, Björnsdóttir US, Bourdin A, Busby J, Canonica GW, Christoff GC, Cosio BG, Costello RW, FitzGerald JM, Fonseca JA, Hansen S, Heaney LG, Heffler E, Hew M, Iwanaga T, Jackson DJ, Kocks JWH, Kallieri M, Bruce Ko HK, Koh MS, Larenas-Linnemann D, Lehtimäki LA, Loukides S, Lugogo N, Maspero J, Papaioannou AI, Perez-de-Llano L, Pitrez PM, Popov TA, Rasmussen LM, Rhee CK, Sadatsafavi M, Schmid J, Siddiqui S, Taillé C, Taube C, Torres-Duque CA, Ulrik C, Upham JW, Wang E, Wechsler ME, Bulathsinhala L, Carter V, Chaudhry I, Eleangovan N, Hosseini N, Rowlands MA, Price D, van Boven JF.
PMID: 34990866
J Allergy Clin Immunol Pract. 2022 Jan 03; doi: 10.1016/j.jaip.2021.12.027. Epub 2022 Jan 03.

BACKGROUND: Regulatory bodies have approved five biologics for severe asthma. However, regional differences in accessibility may limit the global potential for personalized medicine.OBJECTIVE: To compare global differences in ease-of-access to biologics.METHODS: In April 2021, national prescription criteria for omalizumab,...

Cite
Porsbjerg CM, Menzies-Gow AN, Tran TN, et al. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. J Allergy Clin Immunol Pract. 2022;doi: 10.1016/j.jaip.2021.12.027.
Porsbjerg, C. M., Menzies-Gow, A. N., Tran, T. N., Murray, R. B., Unni, B., Audrey Ang, S. L., Alacqua, M., Al-Ahmad, M., Al-Lehebi, R., Altraja, A., Belevskiy, A. S., Björnsdóttir, U. S., Bourdin, A., Busby, J., Canonica, G. W., Christoff, G. C., Cosio, B. G., Costello, R. W., FitzGerald, J. M., Fonseca, J. A., Hansen, S., Heaney, L. G., Heffler, E., Hew, M., Iwanaga, T., Jackson, D. J., Kocks, J. W. H., Kallieri, M., Bruce Ko, H. K., Koh, M. S., Larenas-Linnemann, D., Lehtimäki, L. A., Loukides, S., Lugogo, N., Maspero, J., Papaioannou, A. I., Perez-de-Llano, L., Pitrez, P. M., Popov, T. A., Rasmussen, L. M., Rhee, C. K., Sadatsafavi, M., Schmid, J., Siddiqui, S., Taillé, C., Taube, C., Torres-Duque, C. A., Ulrik, C., Upham, J. W., Wang, E., Wechsler, M. E., Bulathsinhala, L., Carter, V., Chaudhry, I., Eleangovan, N., Hosseini, N., Rowlands, M. A., Price, D., & van Boven, J. F. (2022). Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. The journal of allergy and clinical immunology. In practice, . https://doi.org/10.1016/j.jaip.2021.12.027
Porsbjerg, Celeste M, et al. "Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma." The journal of allergy and clinical immunology. In practice vol. (2022). doi: https://doi.org/10.1016/j.jaip.2021.12.027
Porsbjerg CM, Menzies-Gow AN, Tran TN, Murray RB, Unni B, Audrey Ang SL, Alacqua M, Al-Ahmad M, Al-Lehebi R, Altraja A, Belevskiy AS, Björnsdóttir US, Bourdin A, Busby J, Canonica GW, Christoff GC, Cosio BG, Costello RW, FitzGerald JM, Fonseca JA, Hansen S, Heaney LG, Heffler E, Hew M, Iwanaga T, Jackson DJ, Kocks JWH, Kallieri M, Bruce Ko HK, Koh MS, Larenas-Linnemann D, Lehtimäki LA, Loukides S, Lugogo N, Maspero J, Papaioannou AI, Perez-de-Llano L, Pitrez PM, Popov TA, Rasmussen LM, Rhee CK, Sadatsafavi M, Schmid J, Siddiqui S, Taillé C, Taube C, Torres-Duque CA, Ulrik C, Upham JW, Wang E, Wechsler ME, Bulathsinhala L, Carter V, Chaudhry I, Eleangovan N, Hosseini N, Rowlands MA, Price D, van Boven JF. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. J Allergy Clin Immunol Pract. 2022 Jan 03; doi: 10.1016/j.jaip.2021.12.027. Epub 2022 Jan 03. PMID: 34990866.
Copy Download .nbib Format: NLM
Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.

The American journal of emergency medicine

Lipe DN, Rajha E, Wechsler AH, Gaeta S, Palaskas NL, Alhajji Z, Viets-Upchurch J, Chaftari P.
PMID: 34274878
Am J Emerg Med. 2021 Dec;50:51-58. doi: 10.1016/j.ajem.2021.07.014. Epub 2021 Jul 13.

INTRODUCTION: The expanding use of immunotherapy and the growing population of patients with cancer has led to an increase in the reporting of immune related adverse events (irAEs). The emergency clinician should be aware of these emerging toxicities, some...

Cite
Lipe DN, Rajha E, Wechsler AH, et al. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. Am J Emerg Med. 2021;50:51-58doi: 10.1016/j.ajem.2021.07.014.
Lipe, D. N., Rajha, E., Wechsler, A. H., Gaeta, S., Palaskas, N. L., Alhajji, Z., Viets-Upchurch, J., & Chaftari, P. (2021). Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. The American journal of emergency medicine, 5051-58. https://doi.org/10.1016/j.ajem.2021.07.014
Lipe, Demis N, et al. "Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy." The American journal of emergency medicine vol. 50 (2021): 51-58. doi: https://doi.org/10.1016/j.ajem.2021.07.014
Lipe DN, Rajha E, Wechsler AH, Gaeta S, Palaskas NL, Alhajji Z, Viets-Upchurch J, Chaftari P. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. Am J Emerg Med. 2021 Dec;50:51-58. doi: 10.1016/j.ajem.2021.07.014. Epub 2021 Jul 13. PMID: 34274878.
Copy Download .nbib Format: NLM
Peer review.

The Journal of thoracic and cardiovascular surgery

Wechsler AS, Fried PW.
PMID: 14688670
J Thorac Cardiovasc Surg. 2003 Dec;126(6):1681-2. doi: 10.1016/j.jtcvs.2003.07.015.

No abstract available.

Cite
Wechsler AS, Fried PW. Peer review. J Thorac Cardiovasc Surg. 2003;126(6):1681-2doi: 10.1016/j.jtcvs.2003.07.015.
Wechsler, A. S., & Fried, P. W. (2003). Peer review. The Journal of thoracic and cardiovascular surgery, 126(6), 1681-2. https://doi.org/10.1016/j.jtcvs.2003.07.015
Wechsler, Andrew S, and Fried, Pamela W. "Peer review." The Journal of thoracic and cardiovascular surgery vol. 126,6 (2003): 1681-2. doi: https://doi.org/10.1016/j.jtcvs.2003.07.015
Wechsler AS, Fried PW. Peer review. J Thorac Cardiovasc Surg. 2003 Dec;126(6):1681-2. doi: 10.1016/j.jtcvs.2003.07.015. PMID: 14688670.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 163 entries